These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30675718)

  • 21. Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
    Horikawa H; Kurihara Y; Funakoshi T; Umegaki-Arao N; Takahashi H; Kubo A; Tanikawa A; Kodani N; Minami Y; Meguro S; Itoh H; Izumi K; Nishie W; Shimizu H; Amagai M; Yamagami J
    Br J Dermatol; 2018 Jun; 178(6):1462-1463. PubMed ID: 29478242
    [No Abstract]   [Full Text] [Related]  

  • 22. Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.
    Lindgren O; Varpuluoma O; Tuusa J; Ilonen J; Huilaja L; Kokkonen N; Tasanen K
    Acta Derm Venereol; 2019 May; 99(6):602-609. PubMed ID: 30848289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bullous pemphigoid associated with psoriasis: A possible example of an inverse intramolecular epitope-spreading phenomenon.
    Okahashi K; Oiso N; Ishii N; Uchida S; Matsuda H; Hashimoto T; Kawada A
    J Dermatol; 2015 Jul; 42(7):758-9. PubMed ID: 25903258
    [No Abstract]   [Full Text] [Related]  

  • 24. [Confirmation of gliptin-associated risk of bullous pemphigoid].
    Schmutz JL
    Ann Dermatol Venereol; 2019 Nov; 146(11):764-766. PubMed ID: 31601438
    [No Abstract]   [Full Text] [Related]  

  • 25. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: the importance of the pharmacotherapeutic history.
    García-Gil MF; Lezcano Biosca V; García García M; Monte Serrano J; Aldea Manrique B
    Postgrad Med J; 2021 Jan; 97(1143):51-52. PubMed ID: 32198232
    [No Abstract]   [Full Text] [Related]  

  • 26. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
    Wada N; Uchi H; Furue M
    J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
    [No Abstract]   [Full Text] [Related]  

  • 27. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor - A case report.
    Karthik S; Joseph PE; Babu T
    J Postgrad Med; 2019; 65(4):244-246. PubMed ID: 31535624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid.
    Kamata M; Asano Y; Shida R; Maeda N; Yoshizaki A; Miyagaki T; Kawashima T; Tada Y; Sato S
    J Dermatol; 2019 Jun; 46(6):e216-e217. PubMed ID: 30628103
    [No Abstract]   [Full Text] [Related]  

  • 29. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid.
    Di Zenzo G; Thoma-Uszynski S; Fontao L; Calabresi V; Hofmann SC; Hellmark T; Sebbag N; Pedicelli C; Sera F; Lacour JP; Wieslander J; Bruckner-Tuderman L; Borradori L; Zambruno G; Hertl M
    Clin Immunol; 2008 Sep; 128(3):415-26. PubMed ID: 18571472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gliptins: bullous pemphigoid.
    Prescrire Int; 2015 Mar; 24(158):70. PubMed ID: 25897459
    [No Abstract]   [Full Text] [Related]  

  • 31. Dipeptidyl Peptidase-4 Inhibitor Induced Bullous Pemphigoid Complicated by Acquired Reactive Perforating Dermatosis.
    Gambichler T; Espey B; Doerler M; Stranzenbach R
    Actas Dermosifiliogr; 2022 Oct; 113(9):914-915. PubMed ID: 35636509
    [No Abstract]   [Full Text] [Related]  

  • 32. Possible correlation of IgE autoantibody to BP180 with disease activity in bullous pemphigoid.
    Kamiya K; Aoyama Y; Noda K; Miyake T; Yamaguchi M; Hamada T; Tokura Y; Iwatsuki K
    J Dermatol Sci; 2015 Apr; 78(1):77-9. PubMed ID: 25771164
    [No Abstract]   [Full Text] [Related]  

  • 33. Teneligliptin-associated bullous pemphigoid in an elderly man with diabetes.
    Guliani A; Bishnoi A; Aggarwal D; Parsad D
    Postgrad Med J; 2018 Nov; 94(1117):662-663. PubMed ID: 30317183
    [No Abstract]   [Full Text] [Related]  

  • 34. Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases.
    Jha A; Misra A; Gupta R; Ghosh A; Tyagi K; Dutta K; Arora B; Durani S
    Diabetes Metab Syndr; 2020; 14(3):213-216. PubMed ID: 32172176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoantibodies against type XVII collagen C-terminal domain in a patient with bullous pemphigoid associated with psoriasis vulgaris.
    Inokuma D; Kodama K; Natsuga K; Kasai M; Abe M; Nishie W; Abe R; Hashimoto T; Shimizu H
    Br J Dermatol; 2009 Feb; 160(2):451-4. PubMed ID: 19077079
    [No Abstract]   [Full Text] [Related]  

  • 36. A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: Is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading?
    Amber KT; Zikry J; Hertl M
    HLA; 2017 Mar; 89(3):127-134. PubMed ID: 28101965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linagliptin-associated bullous pemphigoid that was most likely caused by IgG autoantibodies against the midportion of BP180.
    Sakai A; Shimomura Y; Ansai O; Saito Y; Tomii K; Tsuchida Y; Iwata H; Ujiie H; Shimizu H; Abe R
    Br J Dermatol; 2017 Feb; 176(2):541-543. PubMed ID: 27714780
    [No Abstract]   [Full Text] [Related]  

  • 38. Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma.
    Harada M; Yoneda A; Haruyama S; Yabuki K; Honma Y; Hiura M; Shibata M; Matsuoka H; Uchiwa Y
    Intern Med; 2017 Sep; 56(18):2471-2474. PubMed ID: 28824076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BP180 Autoantibodies Target Different Epitopes in Multiple Sclerosis or Alzheimer's Disease than in Bullous Pemphigoid.
    Tuusa J; Lindgren O; Tertsunen HM; Nishie W; Kokkonen N; Huilaja L; Izumi K; Herukka SK; Miettunen J; Shimizu H; Remes AM; Tasanen K
    J Invest Dermatol; 2019 Feb; 139(2):293-299. PubMed ID: 30315782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating IgE anti-BP180 autoantibody and its correlation to clinical and laboratorial aspects in bullous pemphigoid patients.
    Ma L; Wang M; Wang X; Chen X; Zhu X
    J Dermatol Sci; 2015 Apr; 78(1):76-7. PubMed ID: 25797173
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.